Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) – Stock analysts at Zacks Investment Research cut their FY2017 earnings per share (EPS) estimates for shares of Eyegate Pharmaceuticals in a research report issued to clients and investors on Monday, Zacks Investment Research reports. Zacks Investment Research analyst B. Marckx now forecasts that the specialty pharmaceutical company will post earnings of ($1.05) per share for the year, down from their previous forecast of ($0.97). Zacks Investment Research also issued estimates for Eyegate Pharmaceuticals’ Q4 2017 earnings at ($0.26) EPS and FY2018 earnings at ($0.61) EPS.
Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Eyegate Pharmaceuticals in a research report on Thursday, November 9th.
Eyegate Pharmaceuticals (NASDAQ EYEG) opened at $1.16 on Wednesday. Eyegate Pharmaceuticals has a 52-week low of $0.90 and a 52-week high of $3.90. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 0.01.
A hedge fund recently bought a new stake in Eyegate Pharmaceuticals stock. Sabby Management LLC bought a new position in shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 345,524 shares of the specialty pharmaceutical company’s stock, valued at approximately $473,000. Sabby Management LLC owned approximately 2.01% of Eyegate Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 11.94% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Analysts Reduce Earnings Estimates for Eyegate Pharmaceuticals, Inc. (EYEG)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/12/08/fy2017-earnings-forecast-for-eyegate-pharmaceuticals-inc-eyeg-issued-by-zacks-investment-research.html.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Get a free copy of the Zacks research report on Eyegate Pharmaceuticals (EYEG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.